enGene Holdings Inc. (ENGN)

enGene Holdings Income Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021
Selling, General & Admin	28.69	23.98	9.6	3.96	3.41
Research & Development	94.48	38.32	16.46	15.47	12.46
Operating Expenses	123.17	62.3	26.06	19.43	15.87
Operating Income	-123.17	-62.3	-26.06	-19.43	-15.87
Interest Expense	-2.99	-2.8	-4.95	-1.42	-5.02
Interest & Investment Income	9.43	10.41	1.12	0.13	0.03
Currency Exchange Gain (Loss)	-0.57	-0.11	-0.13	-0.7	-0.1
Other Non Operating Income (Expenses)	-	-	-10.57	-3.02	-4.2
EBT Excluding Unusual Items	-117.3	-54.8	-40.6	-24.44	-25.17
Other Unusual Items	-	-0.37	-59.3	-	1.73
Pretax Income	-117.3	-55.16	-99.9	-24.44	-23.44
Income Tax Expense	-	-0.02	0.02	0.02	-
Net Income	-117.3	-55.14	-99.92	-24.46	-23.44
Preferred Dividends & Other Adjustments	-	-	4.82	4.56	-1.19
Net Income to Common	-117.3	-55.14	-104.74	-29.02	-22.25
Shares Outstanding (Basic)	51	38	1	1	4
Shares Outstanding (Diluted)	51	38	1	1	4
Shares Change (YoY)	35.30%	5355.08%	5.72%	-81.61%	28.93%
EPS (Basic)	-2.29	-1.46	-151.22	-44.30	-6.25
EPS (Diluted)	-2.29	-1.46	-151.22	-44.30	-6.25
Free Cash Flow	-100.72	-49.21	-25.06	-17.75	-16.23
Free Cash Flow Per Share	-1.97	-1.30	-36.18	-27.09	-4.56
EBITDA	-122.66	-61.97	-25.89	-19.19	-15.6
D&A For EBITDA	0.51	0.32	0.18	0.24	0.27
EBIT	-123.17	-62.3	-26.06	-19.43	-15.87

Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q